AOD-9604 targets fat cells directly, promoting their breakdown, while MOTS-C improves overall metabolic function and insulin sensitivity
However, based on animal research and anecdotal user reports , we can estimate its half-life and systemic duration depending on how its administeredeither injectable or oral
PubMed DOI Lau JL, Dunn MK (2018)
Relevant Research Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomised controlled trials Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials Retatrutidea game changer in obesity pharmacotherapy Unleashing the power of retatrutide: a possible triumph over obesity Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomised phase 2a trial Retatrutide in type 2 diabetes mellitus and obesity: an overview
Semaglutide GLP-1 Agonist Mimics GLP-1 (glucagon-like peptide-1), a hormone released by your gut after eating
